#USA #Patient Support #Washington, California #BeOne Medicines #Blood Cancer United

Blood Cancer United and BeOne Medicines: A Powerful Collaboration for Improved Patient Support

In a significant move for the oncology sector, Blood Cancer United has announced a robust multi-year expansion in its partnership with BeOne Medicines, an innovative global oncology firm. This collaboration aims to provide enhanced support and education for individuals affected by blood cancer, emphasizing a holistic approach to care that encompasses both medical treatment and community engagement.

Dr. E. Anders Kolb, President and CEO of Blood Cancer United, highlighted the core tenet of this partnership: "No one should face blood cancer alone." With this renewed commitment, both organizations strive to empower patients and their families with vital knowledge and resources. This initiative marks a pivotal expansion in services offered to those navigating the complexities of blood cancer, from initial diagnosis through survivorship, underscoring the importance of community and shared experiences in the healing process.

Investment and Resource Expansion

Under this new collaborative framework known as United for Support and United for Community, BeOne Medicines is making a formidable investment of $5 million over the next three years. This funding builds upon previous support exceeding $3.2 million since 2022, aimed specifically at broadening access to Blood Cancer United's trusted resources. The partnership will significantly augment connections to care while mobilizing community networks nationwide, ultimately enhancing patient experiences along the entire blood cancer continuum.

John V. Oyler, Co-Founder and CEO of BeOne Medicines, reiterated his company's commitment to patient-centric care. He stated, "Putting patients first is a guiding principle for us. Supporting Blood Cancer United's mission to reach more individuals with education and resources reflects our core values, highlighting the need for foundational support alongside innovative treatment developments."

Comprehensive Educational Support

One of the primary focuses of the partnership is to deliver timely and accurate information alongside personalized support for patients dealing with blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL). Some notable initiatives include:

1. Expert-led Educational Webcasts: These webcasts will provide essential information and updates on treatment options, new therapies, and survivorship strategies.
2. Clinical Trial Support Center (CTSC): This center will guide patients in discovering and accessing relevant clinical trials that suit their individual situations.
3. Blood Cancer Conferences: Both virtual and in-person events across the country will deliver free educational content, facilitating discussions around treatment options and recovery support.
4. Uniter™ Platform Expansion: This innovative platform integrates with healthcare systems, connecting patients to personalized support more effectively from the onset of their diagnosis.
5. Advocacy Initiatives: Collaborative efforts will focus on empowering patients to raise their voices and advocate for improved access to treatments and care through public policy initiatives.

Building Community Through Connection

Another key pillar of the partnership, United for Community, emphasizes fostering connections among patients, families, caregivers, employees, and advocates. Through community-driven events like Light The Night, Blood Cancer United's flagship initiative, the collaboration aims to enhance participation and awareness surrounding blood cancer issues. BeOne Medicines has proudly served as the National Presenting Sponsor of Survivorship Hope since 2024, committing to support about 100 events yearly through 2030.

Impact and Aspirations

With a strategic investment and a comprehensive approach, this partnership is poised to significantly enhance patient support services. Key objectives include expanding access to lifesaving information, strengthening patient connections to care, increasing community engagement, and elevating patient voices for impactful policy changes. Blood Cancer United aims to empower patients to gain more than one million years of life by the year 2040, showcasing the ambitious goals set by this partnership.

Conclusion: A New Era in Blood Cancer Care

As Blood Cancer United and BeOne Medicines join forces to overcome the vast challenges posed by blood cancer, this partnership stands as a testament to the dedication of both organizations toward transforming patient care. Through innovative educational initiatives, substantial investment in resources, and unwavering community support, they are paving the way for a brighter future for those affected by blood cancer.

For more information, visit Blood Cancer United and BeOne Medicines.